Genocea Biosciences (GNCA) 4.07 $GNCA
Genocea to Host Second Quarter 2016 Financial Results Conference Call & Webcast on August 4, 2016
GlobeNewswire - Thu Jul 28, 7:00AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, August 4, 2016 at 9:00 a.m. ET to discuss financial results for the second quarter of 2016. Genocea management will provide an update on the Company's recent progress and upcoming milestones.
GNCA: 4.07 (unch)
Anti-Infectives Rx Brings Together Leading Experts to Discuss Development of Anti-Infective, Antiviral, and Antibacterial Therapies
PRWeb - Wed Jul 27, 7:09AM CDT
Industry leaders and decision makers will discuss tackling resistance, social responsibility, the regulatory landscape, breakthroughs in infectious disease and more. Rita Colwell, former Director of the National Science Foundation will deliver a keynote, Sandra Burchett of Boston Children's Hospital will join David Knipe of Harvard Medical School to discuss the Zika Outbreak and Response. A Microbiome focused panel has also been added recently. Other confirmed participants include Marianne De Backer (VP, Johnson & Johnson Innovation), Shyam Bishen (Deputy Director, Bill and Melinda Gates Foundation), John Farley (Deputy Director, Antimicrobial Products, FDA), Shalabh Gupta (CEO, Globavir BioSciences), Jay Luly (CEO, Enanta), Ankit Mahadevia (CEO, Spero Therapeutics), Steve Projan (SVP, MedImmune), Rene Russo (President & CEO, Arsanis) among others. Leading investors from ARCH Venture Partners, Longwood Fund, MP Healthcare, Piper Jaffray, New Enterprise Associates and Versant Ventures will also be in attendance.
GNCA: 4.07 (unch)
Genocea Appoints Ron Cooper to Board of Directors
GlobeNewswire - Thu Jun 09, 3:30PM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Ron Cooper has joined its board of directors, effective immediately. Mr. Cooper currently serves as president and chief executive officer at Albireo Ltd.
GNCA: 4.07 (unch), BMY: 74.81 (+0.15)
Genocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016
GlobeNewswire - Thu Jun 09, 6:30AM CDT
- Presentation of GEN-003 12-Month Data Featured in ASM Press Briefing -
GNCA: 4.07 (unch)
What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.55 (+0.20), INSY: 15.65 (+0.01), AGIO: 45.23 (+1.37), GNCA: 4.07 (unch)
Genocea Appoints Dr. John E. Bishop as Senior Vice President of Pharmaceutical Sciences
GlobeNewswire - Mon May 23, 6:30AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that John E. Bishop, Ph.D. has joined the company as senior vice president of pharmaceutical sciences.
GNCA: 4.07 (unch)
Genocea Biosciences Implements Wingspan eTMF
BusinessWire - Wed May 18, 11:38AM CDT
Genocea Biosciences has partnered with Wingspan Technology to implement a validated, inspection-ready, 21-CFR-Part 11 compliant electronic system. The implementation provides one central location for internal employees, contracted partners, and potential regulatory inspectors to quickly access Genocea's clinical documentation in a controlled environment.
GNCA: 4.07 (unch)
Genocea to Present at the 2016 UBS Global Healthcare Conference
GlobeNewswire - Tue May 17, 7:00AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the upcoming 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016 at 9:00 a.m. ET in New York, NY.
GNCA: 4.07 (unch)
Genocea Biosciences reports 1Q loss
Automated Insights - Thu May 05, 8:29AM CDT
CAMBRIDGE, Mass. (AP) _ Genocea Biosciences Inc. (GNCA) on Thursday reported a loss of $9.8 million in its first quarter.
GNCA: 4.07 (unch)
Genocea Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 7:05AM CDT
- Positive 12-month efficacy data for GEN-003 for genital herpes strengthens value proposition -
GNCA: 4.07 (unch)
Regeneron (REGN) Q1 Earnings: Stock Likely to Disappoint
Zacks Equity Research - Zacks Investment Research - Mon May 02, 10:54AM CDT
Regeneron Pharmaceuticals (REGN), which is set to report first-quarter 2016 results on May 5, recorded a negative earnings surprise of 45.93% last quarter.
GNCA: 4.07 (unch), SNY: 42.63 (+0.03), REGN: 425.12 (+14.08)
Celldex (CLDX): What's Ahead for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 10:52AM CDT
Celldex (CLDX) is expected to report first-quarter 2016 results on May 4.
ZTS: 50.47 (+0.41), CLDX: 4.62 (-0.10), GNCA: 4.07 (unch), BMY: 74.81 (+0.15)
Endo (ENDP) Q1 Earnings: What's in Store for the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:58AM CDT
Endo International (ENDP), which is set to report first-quarter 2016 results on May 5, delivered a positive earnings surprise of 7.09% last quarter.
IPXL: 31.42 (-0.05), ENDP: 17.36 (-0.53), JAZZ: 150.97 (-1.85), GNCA: 4.07 (unch)
Zoetis (ZTS): Stock Likely to Beat on Earnings in Q1 Again?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:56AM CDT
Zoetis (ZTS), which is set to report first-quarter 2016 results on May 4, delivered a positive earnings surprise of 10.26% last quarter.
ZTS: 50.47 (+0.41), ABT: 44.75 (+0.30), JAZZ: 150.97 (-1.85), GNCA: 4.07 (unch)
Genocea to Host First Quarter 2016 Financial Results Conference Call & Webcast on May 5, 2016
GlobeNewswire - Thu Apr 28, 7:02AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, May 5, 2016 at 9:00 a.m. ET to discuss financial results for the first quarter of 2016. Genocea management will provide an update on the Company's recent progress and upcoming milestones.
GNCA: 4.07 (unch)
Mylan (MYL) Q1 Earnings: What's in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 6:20AM CDT
Mylan (MYL), which is set to report first-quarter 2016 results on May 3, delivered a negative earnings surprise of 2.40% in the last quarter.
MYL: 46.79 (+0.07), AGIO: 45.23 (+1.37), GNCA: 4.07 (unch), SNY: 42.63 (+0.03)
Genocea Congratulates Dr. George Siber, 2016 Albert B. Sabin Gold Medal Award Recipient
GlobeNewswire - Wed Apr 20, 7:00AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, is delighted to congratulate Dr. George R. Siber, board member and chair of Genocea's scientific advisory boards, on being awarded the 2016 Albert B. Sabin Gold Medal Award by the Sabin Vaccine Institute. The award recognizes his research contributions in the development of innovative vaccines, including the first pneumococcal conjugate vaccine, the first meningococcal conjugate vaccine and the first antibody for the prevention of RSV infections. He was also involved in development of the first rotavirus vaccine and live attenuated influenza vaccine. This prestigious honor -- the highest scientific honor granted by the Sabin Vaccine Institute and one of the most important in the field of vaccinology -- is awarded annually to a distinguished member of the public health community who has pioneered work in vaccinology or a complementary field.
GNCA: 4.07 (unch)
3 Scorching Hot Healthcare Stocks -- Are They Buys?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 13, 7:03AM CDT
SOURCE: FLICKR USER PICTURES OF MONEY. Worries over payer pushback on sky-high prices have taken a toll on many healthcare stocks, but some stocks are bucking the trend and rewarding investors with eye-popping returns. Among the best performing of...
ISRG: 695.76 (+5.67), CPXX: 30.24 (unch), GNCA: 4.07 (unch), TRXC: 1.35 (+0.04)
Zacks Investment Ideas feature highlights: Juno Therapeutics, Genocea Biosciences, Merrimack Pharmaceuticals and BioShares Biotechnology Clinical Trials ETF
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 8:30AM CDT
Zacks Investment Ideas feature highlights: Juno Therapeutics, Genocea Biosciences, Merrimack Pharmaceuticals and BioShares Biotechnology Clinical Trials ETF
MACK: 5.80 (+0.19), BBC: 19.90 (-0.10), GNCA: 4.07 (unch), JUNO: 30.93 (+1.02)
Genocea to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 06, 7:07AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the upcoming 15 Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 9:20 a.m. ET in New York, NY.
GNCA: 4.07 (unch)
Genocea to Host Second Quarter 2016 Financial Results Conference Call & Webcast on August 4, 2016
GlobeNewswire - Thu Jul 28, 7:00AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, August 4, 2016 at 9:00 a.m. ET to discuss financial results for the second quarter of 2016. Genocea management will provide an update on the Company's recent progress and upcoming milestones.
GNCA: 4.07 (unch)
Anti-Infectives Rx Brings Together Leading Experts to Discuss Development of Anti-Infective, Antiviral, and Antibacterial Therapies
PRWeb - Wed Jul 27, 7:09AM CDT
Industry leaders and decision makers will discuss tackling resistance, social responsibility, the regulatory landscape, breakthroughs in infectious disease and more. Rita Colwell, former Director of the National Science Foundation will deliver a keynote, Sandra Burchett of Boston Children's Hospital will join David Knipe of Harvard Medical School to discuss the Zika Outbreak and Response. A Microbiome focused panel has also been added recently. Other confirmed participants include Marianne De Backer (VP, Johnson & Johnson Innovation), Shyam Bishen (Deputy Director, Bill and Melinda Gates Foundation), John Farley (Deputy Director, Antimicrobial Products, FDA), Shalabh Gupta (CEO, Globavir BioSciences), Jay Luly (CEO, Enanta), Ankit Mahadevia (CEO, Spero Therapeutics), Steve Projan (SVP, MedImmune), Rene Russo (President & CEO, Arsanis) among others. Leading investors from ARCH Venture Partners, Longwood Fund, MP Healthcare, Piper Jaffray, New Enterprise Associates and Versant Ventures will also be in attendance.
GNCA: 4.07 (unch)
Genocea Appoints Ron Cooper to Board of Directors
GlobeNewswire - Thu Jun 09, 3:30PM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Ron Cooper has joined its board of directors, effective immediately. Mr. Cooper currently serves as president and chief executive officer at Albireo Ltd.
GNCA: 4.07 (unch), BMY: 74.81 (+0.15)
Genocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016
GlobeNewswire - Thu Jun 09, 6:30AM CDT
- Presentation of GEN-003 12-Month Data Featured in ASM Press Briefing -
GNCA: 4.07 (unch)
What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.55 (+0.20), INSY: 15.65 (+0.01), AGIO: 45.23 (+1.37), GNCA: 4.07 (unch)
Genocea Appoints Dr. John E. Bishop as Senior Vice President of Pharmaceutical Sciences
GlobeNewswire - Mon May 23, 6:30AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that John E. Bishop, Ph.D. has joined the company as senior vice president of pharmaceutical sciences.
GNCA: 4.07 (unch)
Genocea Biosciences Implements Wingspan eTMF
BusinessWire - Wed May 18, 11:38AM CDT
Genocea Biosciences has partnered with Wingspan Technology to implement a validated, inspection-ready, 21-CFR-Part 11 compliant electronic system. The implementation provides one central location for internal employees, contracted partners, and potential regulatory inspectors to quickly access Genocea's clinical documentation in a controlled environment.
GNCA: 4.07 (unch)
Genocea to Present at the 2016 UBS Global Healthcare Conference
GlobeNewswire - Tue May 17, 7:00AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the upcoming 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016 at 9:00 a.m. ET in New York, NY.
GNCA: 4.07 (unch)
Genocea Biosciences reports 1Q loss
Automated Insights - Thu May 05, 8:29AM CDT
CAMBRIDGE, Mass. (AP) _ Genocea Biosciences Inc. (GNCA) on Thursday reported a loss of $9.8 million in its first quarter.
GNCA: 4.07 (unch)
Genocea Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 7:05AM CDT
- Positive 12-month efficacy data for GEN-003 for genital herpes strengthens value proposition -
GNCA: 4.07 (unch)
Regeneron (REGN) Q1 Earnings: Stock Likely to Disappoint
Zacks Equity Research - Zacks Investment Research - Mon May 02, 10:54AM CDT
Regeneron Pharmaceuticals (REGN), which is set to report first-quarter 2016 results on May 5, recorded a negative earnings surprise of 45.93% last quarter.
GNCA: 4.07 (unch), SNY: 42.63 (+0.03), REGN: 425.12 (+14.08)
Celldex (CLDX): What's Ahead for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 10:52AM CDT
Celldex (CLDX) is expected to report first-quarter 2016 results on May 4.
ZTS: 50.47 (+0.41), CLDX: 4.62 (-0.10), GNCA: 4.07 (unch), BMY: 74.81 (+0.15)
Endo (ENDP) Q1 Earnings: What's in Store for the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:58AM CDT
Endo International (ENDP), which is set to report first-quarter 2016 results on May 5, delivered a positive earnings surprise of 7.09% last quarter.
IPXL: 31.42 (-0.05), ENDP: 17.36 (-0.53), JAZZ: 150.97 (-1.85), GNCA: 4.07 (unch)
Zoetis (ZTS): Stock Likely to Beat on Earnings in Q1 Again?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:56AM CDT
Zoetis (ZTS), which is set to report first-quarter 2016 results on May 4, delivered a positive earnings surprise of 10.26% last quarter.
ZTS: 50.47 (+0.41), ABT: 44.75 (+0.30), JAZZ: 150.97 (-1.85), GNCA: 4.07 (unch)
Genocea to Host First Quarter 2016 Financial Results Conference Call & Webcast on May 5, 2016
GlobeNewswire - Thu Apr 28, 7:02AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, May 5, 2016 at 9:00 a.m. ET to discuss financial results for the first quarter of 2016. Genocea management will provide an update on the Company's recent progress and upcoming milestones.
GNCA: 4.07 (unch)
Mylan (MYL) Q1 Earnings: What's in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 6:20AM CDT
Mylan (MYL), which is set to report first-quarter 2016 results on May 3, delivered a negative earnings surprise of 2.40% in the last quarter.
MYL: 46.79 (+0.07), AGIO: 45.23 (+1.37), GNCA: 4.07 (unch), SNY: 42.63 (+0.03)
Genocea Congratulates Dr. George Siber, 2016 Albert B. Sabin Gold Medal Award Recipient
GlobeNewswire - Wed Apr 20, 7:00AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, is delighted to congratulate Dr. George R. Siber, board member and chair of Genocea's scientific advisory boards, on being awarded the 2016 Albert B. Sabin Gold Medal Award by the Sabin Vaccine Institute. The award recognizes his research contributions in the development of innovative vaccines, including the first pneumococcal conjugate vaccine, the first meningococcal conjugate vaccine and the first antibody for the prevention of RSV infections. He was also involved in development of the first rotavirus vaccine and live attenuated influenza vaccine. This prestigious honor -- the highest scientific honor granted by the Sabin Vaccine Institute and one of the most important in the field of vaccinology -- is awarded annually to a distinguished member of the public health community who has pioneered work in vaccinology or a complementary field.
GNCA: 4.07 (unch)
3 Scorching Hot Healthcare Stocks -- Are They Buys?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 13, 7:03AM CDT
SOURCE: FLICKR USER PICTURES OF MONEY. Worries over payer pushback on sky-high prices have taken a toll on many healthcare stocks, but some stocks are bucking the trend and rewarding investors with eye-popping returns. Among the best performing of...
ISRG: 695.76 (+5.67), CPXX: 30.24 (unch), GNCA: 4.07 (unch), TRXC: 1.35 (+0.04)
Zacks Investment Ideas feature highlights: Juno Therapeutics, Genocea Biosciences, Merrimack Pharmaceuticals and BioShares Biotechnology Clinical Trials ETF
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 8:30AM CDT
Zacks Investment Ideas feature highlights: Juno Therapeutics, Genocea Biosciences, Merrimack Pharmaceuticals and BioShares Biotechnology Clinical Trials ETF
MACK: 5.80 (+0.19), BBC: 19.90 (-0.10), GNCA: 4.07 (unch), JUNO: 30.93 (+1.02)
Genocea to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 06, 7:07AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the upcoming 15 Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 9:20 a.m. ET in New York, NY.
GNCA: 4.07 (unch)
